Fecal transplantation from humans with obesity to mice drives a selective microbial signature without impacting behavioral and metabolic health.
Sci Rep. 2025-05-02; 15(1):
DOI: 10.1038/s41598-025-99047-z
Lire sur PubMed
https://www.bordeaux-neurocampus.fr/11915
Neyrinck AM(#)(1), Ahmed H(#)(2), Leyrolle Q(#)(1)(3), Leclercq S(4), Amadieu
C(1)(3), Meuronen T(2), Layé S(3), Cani PD(1)(5)(6), Kärkkäinen O(7)(8), Bindels
LB(1)(5), Hanhineva K(2), Delzenne NM(9).
Author information:
(1)Metabolism and Nutrition Research Group, Louvain Drug Research Institute
(LDRI), UCLouvain, Université catholique de Louvain, Brussels, Belgium.
(2)Food Sciences Unit, Department of Life Technologies, University of Turku,
Turku, Finland.
(3)INRAE, Bordeaux INP, NutriNeurO, UMR 1286, Université de Bordeaux, 33000,
Bordeaux, France.
(4)Laboratory of Nutritional Psychiatry, Institute of Neuroscience, UCLouvain,
Université catholique de Louvain, Brussels, Belgium.
(5)WELBIO Department, WEL Research Institute, Wavre, Belgium.
(6)Institute of Experimental and Clinical Research (IREC), UCLouvain, Université
catholique de Louvain, Brussels, Belgium.
(7)School of Pharmacy, University of Eastern Finland, Kuopio, Finland.
(8)Institute of Public Health and Clinical Nutrition, University of Eastern
Finland, Kuopio, Finland.
(9)Metabolism and Nutrition Research Group, Louvain Drug Research Institute
(LDRI), UCLouvain, Université catholique de Louvain, Brussels, Belgium.
.
(#)Contributed equally
Obesity is associated with alterations in the gut microbiome that may contribute
to metabolic and mental health disturbances. Fecal microbiota transplantation
(FMT) from humans to mice is a model proposed to study human
microbiota-associated disorders. In this study, we investigated whether gut
microbiota from human donors with obesity could affect behavior and metabolomic
profiles of mice. Stools from donors with obesity and from lean donors were
inoculated to antibiotic-pretreated mice fed a standard low-fat diet throughout
the experiment. Obese-recipient mice exhibited a lower bacterial alpha-diversity
and limited changes in specific taxa (e.g., an increase in Eubacterium) but were
similar to lean-recipient mice in terms of dietary intake, body weight, fat
mass, anxiety/depression-like behavior and glucose homeostasis. Non-targeted
LC-MS metabolomic analysis revealed no change in the portal and cava serum
samples. However, 1-methylnicotinamide, indole-3-acetic acid (I3A) and
methyllysine were increased in the cecal content of obese-recipient compared to
lean-recipient mice. Microbial metabolites derived from amino acids were
positively correlated with Eubacterium. These results indicate that FMT from
donors with obesity to mice fed chow diet (low in lipids) leads to minor but
persistent change in intestinal microbial-derived metabolites, without
recapitulating the metabolic and behavioral alterations of obesity.
© 2025. The Author(s).
DOI: 10.1038/s41598-025-99047-z
PMCID: PMC12048625
PMID: 40316655 [Indexed for MEDLINE]
Conflict of interest statement: Declarations. Competing interests: OK and KH are
founders of Afekta Technologies Ltd. PDC is inventor on patent applications
dealing with the use of gut bacteria and their components in the treatment of
diseases. PDC was co-founder of The Akkermansia Company and Enterosys. The other
authors report no financial interests or potential conflicts of interest.